Amarin Corp Plc (AMRN)

[bogatie]

LINK to ICER

https://icer-review.org/material/cvd-modeling-analysis-plan/

Click on the link on this page and you'll get the Modeling Plan for their analysis of Vascepa.

The data I've cited are:

NEJM (where the discontinuation rate for Vascepa arm was 9.9%)

Amercian Cardiology article where the adherence rate for Vasepa at first CV event is stated as 18.7%

Love to hear from anyone who really knows the terminology of the trials as "adherence" and "discontinuation". I am very concerned that ICER is going to run the numbers on a drop-out assumption rate of 18.7% not 9/9% and therefore their data is going to assume far more cost to benefit (i.e. assuming to high a rate of people who start Vasepa in their model will discontinue use before the benefit of first event prevention.)

Really want to hear some educated thoughts on this as I intend to engage with ICER soon as their draft date is 24 July, but I also don't want to engage on the issue if I am totally wrong....

Thanks